Clinical Trial Search

Primary: Behavioral Outcomes: Change in the k-Value, a Measure of Delay Discounting of Alcohol — -0.12; -7.42 Change in k-value

Primary: Usability — 81.9 score on a scale — p=<0.001

Primary: Speed Walked During 30 Meter Walk Test — 5.63; 5.65; 5.77; 5.86 meters per second (m/s)

Primary: Part A: Number of Participants With All Adverse Events (AEs) and Serious Adverse Events (SAEs) Through Day 29 — 0; 3; 0; 0 Participants

Primary: Change From Baseline in the 17-item HAM-D Total Score at Day 15 — -11.1; -11.5; -12.5 score on a scale — p=0.6638

Primary: Number of Participants Retained During the 12 Week Technology Supported Physical Activity Intervention Period — 24; 24 Participants

Primary: Grade ≥3 AEs Defined as Definitely, Probably, or Possibly Related to 4D CT Ventilation Image-guided Personalized Radiotherapy — 5 participants

Primary: Fluctuation in Pupil Diameter (Hippus) -Pre Drug Administration — 1.61; 1.71 milliseconds^2 — p=0.64

Primary: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 150 — 2.39; 0.70 Percentage change — p=0.9047

Primary: Number of Participants Who Completed the Explore Stage — 283 Participants

Primary: Detection of Malignancy in Excised Lymph Nodes by Pathology or Labeling With Lymphoseek and/or Panitumumab-IRDye800 — 10; 5; 3; NA Lymph nodes

Primary: User Performance of Pivot Breath Sensor — 68; 2; 70; 0 Participants

Primary: Progression Free Survival — 11.8 months

Primary: Number of Participants With Different Stages of Change in Desire to Quit Smoking — 84; 118; 13 Participants

Primary: Detect by Non-invasive Monitoring a Change in Blood Volume During a Whole Blood Draw — 0; 45 participants